Abstract
A case report of posterior reversible encephalopathy syndrome (PRES) induced by the use of sunitinib is presented in an 81-year-old woman treated with sunitinib for metastatic, interferon α-refractory renal cell carcinoma. During the fourth cycle of sunitinib, she was hospitalized for dizziness followed by brief unconsciousness. The symptomatology improved immediately after sunitinib interruption and recovery was complete after a few weeks. Blood pressure was normal at admission and during hospitalisation. Several cases of PRES related to antiangiogenics have been published. PRES was reported with antibodies such as bevacizumab and with small molecule tyrosine kinase inhibitors such as sorafenib and with thalidomide. PRES was possibly related to hypertension and vasospasm, but in the patient treated with sunitinib, blood pressure was normal before, at and after PRES diagnosis. PRES seems to be a rare complication of all antiangiogenic therapies. It should be suspected in patients at the onset of visual disturbances, headache vomiting and seizures, signs of intracranial hypertension and cerebral edema on the computerized tomography. Most cases spontaneously regress after the interruption of the pathological condition.
Similar content being viewed by others
References
Elahi A, Kelkar P, St Louis EK (2004) Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain-Barre Syndrome. Neurocrit Care 1:465–468
Gokce M, Dogan E, Nacitarhan S et al (2006) Posterior reversible encephalopathy syndrome caused by hypertensive encephalopathy and acute uremia. Neurocrit Care 4:133–136
Motzer RJ, Hutson TE, Tomczak P et al (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement): LBA3 24
Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524
Ozcan C, Wong SJ, Hari P (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354(9):980–982
Allen JA, Adlakha A, Bergethon PR (2006) Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63(10):1475–1478
Govindarajan R, Adusumilli A, Baxter DL et al (2006) Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 24:e48
Pandey R, Patel A, Shah S et al (2006) A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasone-reversible posterior lobe leukoencephalopathy. Leuk Lymphoma 47(7):1431–1434
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Medioni, J., Cojocarasu, O., Banu, E. et al. Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targ Oncol 2, 193–195 (2007). https://doi.org/10.1007/s11523-007-0050-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-007-0050-9